Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. / Pérez-Alós, Laura; Armenteros, Jose Juan Almagro; Madsen, Johannes Roth; Hansen, Cecilie Bo; Jarlhelt, Ida; Hamm, Sebastian Rask; Heftdal, Line Dam; Pries-Heje, Mia Marie; Møller, Dina Leth; Fogh, Kamille; Hasselbalch, Rasmus Bo; Rosbjerg, Anne; Brunak, Søren; Sørensen, Erik; Larsen, Margit Anita Hørup; Ostrowski, Sisse Rye; Frikke-Schmidt, Ruth; Bayarri-Olmos, Rafael; Hilsted, Linda Maria; Iversen, Kasper Karmark; Bundgaard, Henning; Nielsen, Susanne Dam; Garred, Peter.

I: Nature Communications, Bind 13, Nr. 1, 1614, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Pérez-Alós, L, Armenteros, JJA, Madsen, JR, Hansen, CB, Jarlhelt, I, Hamm, SR, Heftdal, LD, Pries-Heje, MM, Møller, DL, Fogh, K, Hasselbalch, RB, Rosbjerg, A, Brunak, S, Sørensen, E, Larsen, MAH, Ostrowski, SR, Frikke-Schmidt, R, Bayarri-Olmos, R, Hilsted, LM, Iversen, KK, Bundgaard, H, Nielsen, SD & Garred, P 2022, 'Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors', Nature Communications, bind 13, nr. 1, 1614. https://doi.org/10.1038/s41467-022-29225-4

APA

Pérez-Alós, L., Armenteros, J. J. A., Madsen, J. R., Hansen, C. B., Jarlhelt, I., Hamm, S. R., Heftdal, L. D., Pries-Heje, M. M., Møller, D. L., Fogh, K., Hasselbalch, R. B., Rosbjerg, A., Brunak, S., Sørensen, E., Larsen, M. A. H., Ostrowski, S. R., Frikke-Schmidt, R., Bayarri-Olmos, R., Hilsted, L. M., ... Garred, P. (2022). Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nature Communications, 13(1), [1614]. https://doi.org/10.1038/s41467-022-29225-4

Vancouver

Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR o.a. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nature Communications. 2022;13(1). 1614. https://doi.org/10.1038/s41467-022-29225-4

Author

Pérez-Alós, Laura ; Armenteros, Jose Juan Almagro ; Madsen, Johannes Roth ; Hansen, Cecilie Bo ; Jarlhelt, Ida ; Hamm, Sebastian Rask ; Heftdal, Line Dam ; Pries-Heje, Mia Marie ; Møller, Dina Leth ; Fogh, Kamille ; Hasselbalch, Rasmus Bo ; Rosbjerg, Anne ; Brunak, Søren ; Sørensen, Erik ; Larsen, Margit Anita Hørup ; Ostrowski, Sisse Rye ; Frikke-Schmidt, Ruth ; Bayarri-Olmos, Rafael ; Hilsted, Linda Maria ; Iversen, Kasper Karmark ; Bundgaard, Henning ; Nielsen, Susanne Dam ; Garred, Peter. / Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. I: Nature Communications. 2022 ; Bind 13, Nr. 1.

Bibtex

@article{ad2b6932a7d440c0a401a5edadb563fa,

title = "Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors",

abstract = "SARS-CoV-2 vaccines are crucial in controlling COVID-19, but knowledge of which factors determine waning immunity is limited. We examined antibody levels and T-cell gamma-interferon release after two doses of BNT162b2 vaccine or a combination of ChAdOx1-nCoV19 and BNT162b2 vaccines for up to 230 days after the first dose. Generalized mixed models with and without natural cubic splines were used to determine immunity over time. Antibody responses were influenced by natural infection, sex, and age. IgA only became significant in naturally infected. A one-year IgG projection suggested an initial two-phase response in those given the second dose delayed (ChAdOx1/BNT162b2) followed by a more rapid decrease of antibody levels. T-cell responses correlated significantly with IgG antibody responses. Our results indicate that IgG levels will drop at different rates depending on prior infection, age, sex, T-cell response, and the interval between vaccine injections. Only natural infection mounted a significant and lasting IgA response.",

keywords = "Antibodies, Viral, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, Humans, SARS-CoV-2, Vaccination, Vaccines, Inactivated, Viral Vaccines",

author = "Laura P{\'e}rez-Al{\'o}s and Armenteros, {Jose Juan Almagro} and Madsen, {Johannes Roth} and Hansen, {Cecilie Bo} and Ida Jarlhelt and Hamm, {Sebastian Rask} and Heftdal, {Line Dam} and Pries-Heje, {Mia Marie} and M{\o}ller, {Dina Leth} and Kamille Fogh and Hasselbalch, {Rasmus Bo} and Anne Rosbjerg and S{\o}ren Brunak and Erik S{\o}rensen and Larsen, {Margit Anita H{\o}rup} and Ostrowski, {Sisse Rye} and Ruth Frikke-Schmidt and Rafael Bayarri-Olmos and Hilsted, {Linda Maria} and Iversen, {Kasper Karmark} and Henning Bundgaard and Nielsen, {Susanne Dam} and Peter Garred",

note = "{\textcopyright} 2022. The Author(s).",

year = "2022",

doi = "10.1038/s41467-022-29225-4",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "nature publishing group",

number = "1",

}

RIS

TY - JOUR

T1 - Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors

AU - Pérez-Alós, Laura

AU - Armenteros, Jose Juan Almagro

AU - Madsen, Johannes Roth

AU - Hansen, Cecilie Bo

AU - Jarlhelt, Ida

AU - Hamm, Sebastian Rask

AU - Heftdal, Line Dam

AU - Pries-Heje, Mia Marie

AU - Møller, Dina Leth

AU - Fogh, Kamille

AU - Hasselbalch, Rasmus Bo

AU - Rosbjerg, Anne

AU - Brunak, Søren

AU - Sørensen, Erik

AU - Larsen, Margit Anita Hørup

AU - Ostrowski, Sisse Rye

AU - Frikke-Schmidt, Ruth

AU - Bayarri-Olmos, Rafael

AU - Hilsted, Linda Maria

AU - Iversen, Kasper Karmark

AU - Bundgaard, Henning

AU - Nielsen, Susanne Dam

AU - Garred, Peter

PY - 2022

Y1 - 2022

N2 - SARS-CoV-2 vaccines are crucial in controlling COVID-19, but knowledge of which factors determine waning immunity is limited. We examined antibody levels and T-cell gamma-interferon release after two doses of BNT162b2 vaccine or a combination of ChAdOx1-nCoV19 and BNT162b2 vaccines for up to 230 days after the first dose. Generalized mixed models with and without natural cubic splines were used to determine immunity over time. Antibody responses were influenced by natural infection, sex, and age. IgA only became significant in naturally infected. A one-year IgG projection suggested an initial two-phase response in those given the second dose delayed (ChAdOx1/BNT162b2) followed by a more rapid decrease of antibody levels. T-cell responses correlated significantly with IgG antibody responses. Our results indicate that IgG levels will drop at different rates depending on prior infection, age, sex, T-cell response, and the interval between vaccine injections. Only natural infection mounted a significant and lasting IgA response.

AB - SARS-CoV-2 vaccines are crucial in controlling COVID-19, but knowledge of which factors determine waning immunity is limited. We examined antibody levels and T-cell gamma-interferon release after two doses of BNT162b2 vaccine or a combination of ChAdOx1-nCoV19 and BNT162b2 vaccines for up to 230 days after the first dose. Generalized mixed models with and without natural cubic splines were used to determine immunity over time. Antibody responses were influenced by natural infection, sex, and age. IgA only became significant in naturally infected. A one-year IgG projection suggested an initial two-phase response in those given the second dose delayed (ChAdOx1/BNT162b2) followed by a more rapid decrease of antibody levels. T-cell responses correlated significantly with IgG antibody responses. Our results indicate that IgG levels will drop at different rates depending on prior infection, age, sex, T-cell response, and the interval between vaccine injections. Only natural infection mounted a significant and lasting IgA response.

KW - Antibodies, Viral

KW - BNT162 Vaccine

KW - COVID-19/prevention & control

KW - COVID-19 Vaccines

KW - Humans

KW - SARS-CoV-2

KW - Vaccination

KW - Vaccines, Inactivated

KW - Viral Vaccines

U2 - 10.1038/s41467-022-29225-4

DO - 10.1038/s41467-022-29225-4

M3 - Journal article

C2 - 35347129

VL - 13

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1614

ER -

ID: 303110437